Reports & Databases

Subscribe to
our newsletters!

Showing 21–40 of 50 results

  • June of 2019
    This Target Pipeline List provides an overview of P2X3 receptor antagonists in development for treatment of chronic cough, endometriosis and neuropathic pain.
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of FAP-targeted antibodies, fusion proteins and oncolytic viruses in development for treatment of stroma rich tumors.
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of GPC3-targeted antibody and cell therapeutics in development for treatment of hepatocellular carcinoma (HCC)
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of DLL3-targeted antibody and cell therapeutics in development for treatment of small cell lung cancer (SCLC).
     50.00
  • June of 2019
    This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.
     2350.00
  • May of 2019
    This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)
     150.00
  • April of 2019
    This report provides an overview of small molecule inhibitors of Tyk2 in development for treatment of inflammatory diseases.
     125.00
  • April of 2019
    This report provides an overview of small molecule inhibitors of NLRP3 in development for treatment of chronic inflammatory diseases.
     75.00
  • April of 2019
    This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.
     50.00
  • March of 2020
    This report provides an overview of anti-FcRn therapeutic antibodies and proteins in development for treatment of IgG-mediated autoimmune diseases.
     100.00
  • April of 2019
    This report provides an overview of therapeutic proteins in development for treatment of arginine-dependent tumors or for enzyme replacement therapy.
     75.00
  • April of 2019
    This report provides an overview of CD40 agonistic antibodies, proteins or viral vectors in development for treatment of solid tumors as monotherapy or in combination therapy.
     150.00
  • March of 2019
    This report provides a compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies in the calendar year 2018.
     80.00
  • March of 2019
    This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout or tumor lysis
     150.00
  • February of 2019
    This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.
     100.00
  • May of 2018
    These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.
     4450.00  2670.00
  • January of 2019
    This report informs about the competitive field of novel DNA vaccines in clinical development for prevention and/or treatment of cancer, infectious and other diseases.
     400.00